Jiangsu Vcare PharmaTech Co., Ltd., a China – based high – tech pharmaceutical company, has reportedly secured close to RMB200 million (USD27.6 million) in a Series C + financing round. The funding was led by Galaxy Finance, CMG – SDIC Capital, Yangtze River Industry Group, and other investors. The proceeds will be used to accelerate the clinical development of innovative drugs, enhance the industrial chain layout of contract research organization (CRO) and contract development and manufacturing organization (CDMO) services, boost independent innovation capabilities, and expand the company’s presence in the fields of synthetic biology and green chemistry.
Funding and Future Plans
The Series C + financing round underscores Vcare PharmaTech’s strategic focus on advancing its pipeline of innovative drugs and strengthening its CRO/CDMO service offerings. The funds will be allocated towards ramping up clinical development programs, particularly for its lead candidate vicagrel, an oral P2Y12 receptor antagonist currently in Phase III. Additionally, the company plans to invest in expanding its industrial chain layout to enhance efficiency and competitiveness in the CRO/CDMO sector.
Company Background and Pipeline
Founded in 2010, Vcare PharmaTech has grown into a prominent group company with two core businesses: the research and development (R&D) of innovative drugs and full – industry – chain CRO & CDMO services. The company’s robust pipeline includes vicagrel, its Phase III – stage P2Y12 receptor antagonist, as well as five other investigational drugs at various clinical stages. Vcare’s commitment to innovation and sustainable development is further highlighted by its focus on synthetic biology and green chemistry, which align with global trends in pharmaceutical manufacturing and environmental responsibility.-Fineline Info & Tech
Leave a Reply